Lori L. Davis

Lori L. Davis

Auto-generated profile, based on publicly available information

Lori L. Davis

Birmingham VA Health Care System, Birmingham, Alabama, and University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
LDLori Davis
Lori Davis
AUAkihito Uezato
Akihito Uezato
JNJason M Newell
Jason M Newell
EFElizabeth Frazier
Elizabeth Frazier
The presentation of major depressive disorder is often complicated by the co-occurrence of substance use disorders, such as alcohol and illicit drug abuse or dependence. The article reviews the recent systematic research on the distinguishing baseline characteristics including demographic characteristics and the influence of family history, and clinical features such as depressive symptomatology and suicidal ideation, and the outcome of treatment for depression in patients with comorbid major depressive disorder and substance use disorders. The review also addresses the possible explanations cited in the literature as to why these two disorders tend to co-occur and the implications of the comorbidity of these illnesses on treatment. Nearly one-third of patients with major depressive disorder also have substance use disorders, and the comorbidity yields higher risk of suicide and greater social and personal impairment as well as other psychiatric conditions. Although the treatment of comorbid major depressive disorder and substance use disorders with medication is likely effective, the differential treatment effects based on substance use disorder comorbidity have been understudied. Emerging results of recent studies comparing the outcome of major depressive disorder patients with comorbid major depressive disorder and substance use disorders suggest that there are fewer differential effects based on comorbidity than previously anticipated by older assumptions from smaller, less methodologically rigorous studies.

25 April 2022 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
LDLori L. Davis
Lori L. Davis
JSJeff Schein
Jeff Schein
MCMartin Cloutier
Martin Cloutier
PGPatrick Gagnon-Sanschagrin
Patrick Gagnon-Sanschagrin
JMJessica Maitland
Jessica Maitland
CHChristy R. Houle
Christy R. Houle
Objective: To estimate the economic burden of posttraumatic stress disorder (PTSD) in the United States civilian and military populations from a societal perspective. Methods: A prevalence-based and human capital approach was used to estimate the total excess costs of PTSD in 2018 from insurance claims data, academic literature, and governmental publications. Excess direct health care costs (pharmacy, medical), direct non-health care costs (research and training, substance use, psychotherapy, homelessness, disability), and indirect costs (unemployment, productivity loss, caregiving, premature mortality) associated with PTSD were compared between adults with PTSD and adults without PTSD, or the general population if information was not available for adults without PTSD. Results: The total excess economic burden of PTSD in the US was estimated at $232.2 billion for 2018 ($19,630 per individual with PTSD). Total excess costs were $189.5 billion (81.6%) in the civilian population and $42.7 billion (18.4%) in the military population, corresponding to $18,640 and $25,684 per individual with PTSD in the civilian and military populations, respectively. In the civilian population, the excess burden was driven by direct health care ($66.0 billion) and unemployment ($42.7 billion) costs. In the military population, the excess burden was driven by disability ($17.8 billion) and direct health care ($10.1 billion) costs. Conclusions: The economic burden of PTSD goes beyond direct health care costs and has been found to rival costs for other costly mental health conditions. Increased awareness of PTSD, development of more effective therapies, and expansion of evidence-based interventions may be warranted to reduce the large clinical and economic burden of PTSD.

1 February 2008 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
LDLori L. Davis
Lori L. Davis
JDJonathan R.T. Davidson
Jonathan R.T. Davidson
LWL. Charles Ward
L. Charles Ward
ABAl Bartolucci
Al Bartolucci
CBCharles L. Bowden
Charles L. Bowden
FPFrederick Petty
Frederick Petty
To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.

1 May 2012 in Psychiatric Services
Verified
Journal Article
Closed access
PDF file
LDLori L. Davis
Lori L. Davis
ALAndrew C. Leon
Andrew C. Leon
RTRichard Toscano
Richard Toscano
CDCharles E. Drebing
Charles E. Drebing
LWL. Charles Ward
L. Charles Ward
RDRobert E. Drake
Robert E. Drake

1 April 2018 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
LDLori L. Davis
Lori L. Davis
TKTassos C. Kyriakides
Tassos C. Kyriakides
ASAlina M. Suris
Alina M. Suris
LOLisa A. Ottomanelli
Lisa A. Ottomanelli
LMLisa Mueller
Lisa Mueller
RDRobert E. Drake
Robert E. Drake
Posttraumatic stress disorder (PTSD) interferes with a person’s ability to function at work1,2 and negatively affects sustained employment3 and income.4 Veterans who screen positive for PTSD are more likely to be unemployed than are those without PTSD.5 The co-occurrence of PTSD, depression, and mild traumatic brain injury is significantly associated with unemployment compared with mild traumatic brain injury alone.3 Chronic health conditions paired with PTSD significantly increase the odds of early retirement or job loss before age 60 years.6 A 2015 analysis found that veterans’ labor force participation declined over the previous 35 years in close correlation with growth in service-connected disability.7 Without effective intervention, the growing numbers of unemployed prime working-aged individuals with disabling PTSD could have a substantial economic impact for generations to come.

1 March 2010 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
LDLori L. Davis
Lori L. Davis
SWStephen R. Wisniewski
Stephen R. Wisniewski
RHRobert H. Howland
Robert H. Howland
MTMadhukar H. Trivedi
Madhukar H. Trivedi
MHMustafa M. Husain
Mustafa M. Husain
ARA. John Rush
A. John Rush